Explicyte retweeted
@OncoStart facilite la rencontre entre entreprises innovantes et les talents du secteur de l’oncologie.
📣 Dernières offres d’emploi @SmartImmune_off @ExpliCyte
☞ lnkd.in/eTGggdTr
🔔 Publiez vos offres d’emploi (oncologie) lnkd.in/ewyEhJDb
Check out – It’s our favorite image of January!
When science dives into pointillism…What a masterpiece!
Our fish in the ocean highlighting a Peyer’s patch on a human colon FFPE specimen is revealed using our multiplexed TLS detection panel.
bit.ly/3w7873u
A new anti-PD1 resistant mouse sarcoma model, ovarian cancer ascites as a remarkable tool for translational research or our GeoMx platform to support support your spatial transcriptomics programs, check out our best highlights of 2022!
bit.ly/3YDBUOj
Stay connected!
Check out – It’s our ‘UNSHAVED’ image for Movember!
Beyond the mustache, we at Explicyte are calling for awareness to ‘change the face’ of men’s health - mental health issues and especially cancers.
bit.ly/3UMGdnO
#Movember #Cancer #Menshealth #Immunohistofluorescence
Don’t miss to meet us at the @sitcancer Annual Meeting in Boston next week.
Schedule an in-person meeting with us and plan to take a look at our posters!
bit.ly/3DwuiTT
#SITC2022 #cancer #oncology #cancerresearch #SITC22 #immunooncology
We very much look forward to attending the @sitcancer Annual Meeting in Boston from November 8 to 12, and to showcasing our recent research works through our posters.
bit.ly/3gsyMmM
#SITC2022 #cancer #oncology #cancerresearch #SITC22 #immunooncology
Check out – It’s our favorite image of the month!
What a pretty multiplexed image showing the tumor microenvironment (TME) on a human NSCLC section, highlighting PDL1 positive tumor cells surrounded by macrophages and T cells.
bit.ly/3PDsb5h
#Immunohistofluorescence
Discover our main news for the first half of 2022!
Learn about our partnership with @DOMAINtx, new cutting-edge platforms for biomarker translational research as well as our newest featured publications!
bit.ly/3AwgoBe
#CancerResearch #ImmunoOncology #SummerNews
Ascites is a pathological peritoneal fluid accumulation most frequently associated with ovarian cancer, thereby creating a quite unique tumor microenvironment in which cancer cells spread.
Learn more: bit.ly/3NkoYps
#ImmunoOncology #CancerResearch
Check out - it's our favorite image of the month
Summer beginning, look at a real fireworks🎆! Human cerebral cortex nerve cells lit up on section!
Contact us for your digital pathology projects
explicyte.com/news/2022/06/1…
#Immunohistofluorescence #ImmunoOncology #Brain
A new collaborative work reported in Annals of Oncology and featured at ASCO 2022!
Our recent collaboration with @BERGONIE33 and @GustaveRoussy is published: Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
bit.ly/3n8GKBD
#ImmunoOncology
Our Digital Spatial Profiling data reported in the Journal for ImmunoTherapy of Cancer!
Our biomarker discovery platform has been brought to the fore in a recent publication resulting from a close collaboration with @BERGONIE33
bit.ly/3GGQQSW
#DSP #GeoMx @nanostringtech
New! Olink proteomics joins the dance of our biomarker discovery capacities
As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery.
bit.ly/3x03fNj
#Proteomics
Save the date!
We will be attending the @ASCO
Annual Meeting #ASCO2022 in Chicago, from June 3 to 7, 2022.
We are eager to meet you there, discuss your research projects and introduce our service offerings.
bit.ly/3LqeyUh
#CancerResearch #Oncology #Cancer
Spotlight on our in vivo advances : we developed and characterized a novel anti-PD1 resistant sarcoma mouse model!
bit.ly/3FCxazg
#Oncology #ImmunoOncology #CancerResearch #Immunotherapy #InVivoAdvance
We will be attending the #Meet2win event organized by @MATWIN_Bdx on the 12th and 13th of May in Bordeaux.
We will also participate in the Job Dating sessions organized by @OncoStart and @PhDTalent!
#Oncology #ImmunoOncology #JobDating #JobOffer
Meet us at the @nanostringtech and @OGConferences event on May 5!
Our CEO Dr. Alban Bessede will discuss at 9:10 BST recent findings about new mechanisms underlying response to cancer immunotherapies.
bit.ly/39lgv76
#SpatialBiology #Biomarkers #DrugDiscovery
Back from the #AACR2022, it was a pleasure to introduce our posters showcasing our newest preclinical and translational research advances in Immuno-Oncology.
If you didn't get the chance to see our posters, you can download them!
bit.ly/3K3L5Ph
#Oncology #Cancerresearch
We will be attending the @AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there, approach your research projects and introduce our service offerings.
bit.ly/3uGl1UZ
#AACR2022 #Cancer #CancerResearch
Our expertise in multiplexed-immunohistofluorescence (IHF) and ommunohistochemistry (IHC) has been highlited in recent scientific publications of collaborative works with @BERGONIE33
bit.ly/3qzuw6S
#immunology #oncology #immunotherapy #CancerResearch





















